Sep 05, 2023 4:05 pm EDT Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
Aug 29, 2023 4:05 pm EDT Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023
Aug 07, 2023 4:05 pm EDT Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 31, 2023 4:05 pm EDT Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
Jul 17, 2023 4:01 pm EDT Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
May 31, 2023 8:00 am EDT Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference
May 15, 2023 4:01 pm EDT Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 02, 2023 8:00 am EDT Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension
May 01, 2023 8:00 am EDT Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
Apr 27, 2023 4:47 pm EDT Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023